Managing asbestos eradication

Published: 11-Dec-2015

The European Parliament has proposed the removal of asbestos from all European public buildings by 2028. Todd Hallam, Chalcroft’s QEHS Director, looks at how the pharma industry can safely implement an asbestos management plan

You need to be a subscriber to read this article.
Click here to find out more.

An estimated 2,000 deaths from lung cancer are attributed to asbestos exposure each year, and while these figures are slowly decreasing, another illness associated with asbestos is sadly on the rise. Mesothelioma, a more specific form of cancer that often originates in the lung lining, can be caused by a much lower exposure to asbestos and is the cause of an increasing number of deaths. The European Parliament is therefore considering introducing a complete removal of asbestos particles in public and commercial buildings to prevent illness and fatalities – policies which are already in place in Australia and Poland.

After centuries of use, the asbestos industry was established in 1858 when companies began mining the material specifically for industrial insulation. Indeed, the substance is still mined today in countries such as Russia, Brazil, China and Kazakhstan.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cleanroom Technology.

Subscribe now Already a subscriber? Sign in here.

You may also like